DHR vs MRVI
DHR: Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally. MRVI: Maravai LifeSciences provides essential nucleic acid synthesis reagents and bioprocessing analytical tools that underpin the development and manufacturing of next-generation vaccines and therapies.
Side-by-side fundamentals
| Metric | DHR | MRVI | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $217.46 | $7.21 | |
| Market cap | $152.9B | $1.9B | |
| P/E as of 2026-10-08 | 38.61 | n/a | |
| Net margin FY2025, SEC XBRL | +14.7% | -70.4% | DHR higher |
| Gross margin FY2025, SEC XBRL | +59.1% | +18.3% | DHR higher |
| Operating margin FY2025, SEC XBRL | +19.1% | -115.9% | DHR higher |
| ROE FY2025, SEC XBRL | +6.9% | -35.1% | DHR higher |
| ROA FY2025, SEC XBRL | +4.3% | -17.0% | DHR higher |
| Debt / equity as of 2026-09-03 | 0.51 | 0.86 | DHR lower |
| Revenue growth (YoY) as of 2026-09-03 | +4.6% | -3.3% | DHR higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -40.5% | DHR higher |
| Dividend yield as of 2026-09-03 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.78 | 1.38 | |
| 1-year return as of 2026-10-08 close | +6.1% | +116.5% | MRVI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.